Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vasandani, Jitendra
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)	Active, not recruiting	3	292	Europe, Japan, US, RoW	TILD, matching placebo injections	Sun Pharmaceutical Industries Limited	Active Psoriatic Arthritis	09/24	12/24
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)	Recruiting	3	472	Europe, Canada, US, RoW	TILD, matching placebo injections	Sun Pharmaceutical Industries Limited	Active Psoriatic Arthritis	05/25	02/26
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight	Recruiting	3	250	US	Ixekizumab, LY2439821, Tirzepatide, LY3298176	Eli Lilly and Company	Psoriatic Arthritis, Obesity	04/26	08/26
NCT04991116: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis	Recruiting	3	650	Europe, Canada, Japan, US, RoW	TILD sub-cutaneous (SC) injection	Sun Pharmaceutical Industries Limited	Psoriatic Arthritis	12/28	04/29